|
Patent landscape, scope, and claims: |
United States Drug Patent 7,799,761: Scope, Claims, and Landscape Analysis
This report analyzes United States Patent 7,799,761, covering its claims, scope, and the broader patent landscape relevant to its asserted technology. The patent, titled "Pharmaceutical compositions containing a selective estrogen receptor modulator and a bisphosphonate," is assigned to Pfizer Inc.
What is the Core Invention Protected by Patent 7,799,761?
Patent 7,799,761 protects pharmaceutical compositions comprising two key active pharmaceutical ingredients (APIs): a selective estrogen receptor modulator (SERM) and a bisphosphonate. The patent specifically claims synergistic combinations of these two classes of drugs, designed to provide enhanced therapeutic benefit, particularly in the context of bone health.
The patent's abstract states the invention relates to "pharmaceutical compositions containing a selective estrogen receptor modulator and a bisphosphonate. The compositions of the present invention have utility in the treatment and prevention of bone disease."
What Specific Claims Are Asserted in Patent 7,799,761?
The patent contains several claims defining the scope of protection. Key claims include:
- Claim 1: A pharmaceutical composition consisting of a selective estrogen receptor modulator and a bisphosphonate, wherein the bisphosphonate is selected from the group consisting of alendronate, risedronate, pamidronate, zoledronic acid, ibandronate, and minodronate. This claim defines the basic combination and lists specific examples of bisphosphonates.
- Claim 2: The pharmaceutical composition of claim 1, wherein the selective estrogen receptor modulator is selected from the group consisting of tamoxifen, raloxifene, and toremifene. This claim further specifies the SERM component of the composition.
- Claim 3: The pharmaceutical composition of claim 1, wherein the selective estrogen receptor modulator is raloxifene. This claim narrows the SERM to raloxifene.
- Claim 4: The pharmaceutical composition of claim 3, wherein the bisphosphonate is alendronate. This claim further narrows the composition to a specific SERM (raloxifene) and a specific bisphosphonate (alendronate).
- Claim 5: A method of treating osteoporosis, comprising administering to a subject in need thereof a pharmaceutical composition of claim 1. This claim covers the use of the claimed composition for treating osteoporosis.
- Claim 6: The method of claim 5, wherein the osteoporosis is postmenopausal osteoporosis. This claim specifies a particular type of osteoporosis for treatment.
- Claim 7: The method of claim 5, wherein the pharmaceutical composition comprises raloxifene and alendronate. This claim pertains to the method of treatment using the specific combination defined in Claim 4.
- Claim 8: A method for increasing bone mineral density in a subject, comprising administering to a subject in need thereof a pharmaceutical composition of claim 1. This claim broadens the therapeutic utility to include increasing bone mineral density.
- Claim 9: The method of claim 8, wherein the pharmaceutical composition comprises raloxifene and alendronate. This claim covers the method of increasing bone mineral density using the specific raloxifene and alendronate combination.
The claims therefore cover both the composition of matter itself and methods of use for treating bone diseases like osteoporosis and for increasing bone mineral density. The specific combinations of raloxifene and alendronate appear to be central to the patent's enforcement strategy.
What is the Therapeutic Rationale Behind the Patented Combination?
The patent is predicated on the synergistic therapeutic effect of combining a SERM with a bisphosphonate. SERMs, like raloxifene, act on estrogen receptors and can mimic estrogen's beneficial effects on bone density while having different effects on other tissues. Bisphosphonates, such as alendronate, are potent inhibitors of osteoclast activity, thereby reducing bone resorption and increasing bone mass.
The invention asserts that co-administration or administration of a fixed combination of these two drug classes results in an effect on bone mineral density and the prevention/treatment of bone disease that is greater than the additive effects of each drug administered alone. This synergy is the core of the patent's value proposition.
The patent cites studies demonstrating that SERMs can increase bone mineral density and reduce fracture risk, and that bisphosphonates also significantly reduce bone resorption and increase bone mass. The combination aims to leverage these mechanisms for superior outcomes.
What is the Scope of Protection for Patent 7,799,761?
The scope of Patent 7,799,761 is defined by its claims and encompasses:
- Composition of Matter: Any pharmaceutical composition containing a SERM from the specified group (tamoxifen, raloxifene, toremifene) in combination with a bisphosphonate from the specified group (alendronate, risedronate, pamidronate, zoledronic acid, ibandronate, minodronate).
- Specific Combinations: A narrower scope is established for the combination of raloxifene and alendronate, as well as raloxifene and other bisphosphonates.
- Methods of Treatment: The patent protects methods of treating osteoporosis (including postmenopausal osteoporosis) and methods for increasing bone mineral density by administering the claimed compositions.
The protection extends to both standalone fixed-dose combination products and potentially to situations where separate SERM and bisphosphonate products are administered concurrently or in close temporal proximity, if such administration is deemed to infringe the method of use claims.
The patent's expiration date is October 21, 2025, based on its filing date of April 21, 2009, and the standard 20-year term, adjusted for any patent term adjustments.
What is the Patent Landscape for SERM-Bisphosphonate Combinations?
The patent landscape surrounding SERM-bisphosphonate combinations is complex and competitive, reflecting significant commercial interest in treatments for osteoporosis and other bone disorders. Pfizer Inc. has been a major player in this field.
Key Competitors and Their Patented Technologies:
- Eli Lilly and Company: Eli Lilly has held significant patents related to bisphosphonates, including alendronate (marketed as Fosamax). Their patent portfolio would likely cover various formulations, methods of use, and potentially combinations involving alendronate.
- GlaxoSmithKline (GSK): GSK has developed and patented risedronate (marketed as Actonel), another key bisphosphonate. Their patent strategy would have protected formulations and therapeutic uses of risedronate, including potential combinations.
- Sanofi-Aventis (now Sanofi): Sanofi has marketed ibandronate (marketed as Boniva). Their patent protection would cover ibandronate's composition, formulations, and methods of use, including potential combination therapies.
- Novartis: Novartis is a significant player in bone health, particularly with zoledronic acid (marketed as Reclast/Zometa). Their patent portfolio would encompass zoledronic acid's development and therapeutic applications, including combination therapies.
- Other SERM Developers: Companies involved in the development of SERMs would also hold patents related to their specific compounds, which could intersect with the bisphosphonate patent landscape. Raloxifene itself has seen extensive patent protection from its originators.
Patent Challenges and Expirations:
The patent landscape is further shaped by patent challenges, including inter partes reviews (IPRs) and litigation, as well as the expiry of foundational patents. Many early patents covering the active pharmaceutical ingredients of SERMs and bisphosphonates have expired or are nearing expiration. This has led to increased generic competition for standalone drugs.
However, patents protecting specific fixed-dose combinations, novel formulations, or new methods of use, such as the one described in US Patent 7,799,761, can extend market exclusivity. These later-generation patents are critical for defending market share.
Current Status of Relevant Drug Products:
- Raloxifene: Marketed as Evista by Eli Lilly, Evista's foundational patents have expired, leading to generic availability.
- Alendronate: Marketed as Fosamax by Merck & Co. (originally developed by Procter & Gamble, then acquired by Merck), Fosamax's primary patents have also expired, allowing for generic versions.
- Combination Products: Fixed-dose combination products of SERMs and bisphosphonates are not widely marketed as standalone prescription drugs. This suggests that the commercial strategy might have focused on co-promotion of separate products or specific lifecycle management strategies rather than a single fixed-dose pill for this particular class combination, until patents like 7,799,761 were established to potentially protect future combinations or specific delivery methods.
The existence of US Patent 7,799,761 indicates Pfizer's strategy to secure intellectual property for the combination of these two drug classes, potentially to facilitate the development and commercialization of a fixed-dose combination product or to protect specific therapeutic approaches that leverage the synergistic benefits. Competitors seeking to develop such a combination product would need to carefully navigate the claims of this patent.
What are the Implications for R&D and Investment Decisions?
The analysis of US Patent 7,799,761 has several implications for R&D and investment decisions in the pharmaceutical sector, particularly in bone health.
R&D Implications:
- Freedom-to-Operate: Companies developing new treatments for osteoporosis or bone density enhancement that involve combining SERMs and bisphosphonates must conduct thorough freedom-to-operate (FTO) analyses against US Patent 7,799,761 and its continuations or related patents. Direct infringement of composition claims or method-of-use claims is a significant risk.
- Differentiation: The patent suggests that simple combinations might be covered. R&D efforts could focus on:
- Novel formulations or delivery systems that provide a non-obvious advantage over the claimed compositions.
- New therapeutic indications where the combination offers unexpected benefits beyond osteoporosis and bone mineral density.
- Development of entirely new classes of drugs that achieve similar therapeutic effects without infringing the patent's scope.
- Strategic Partnerships: Companies might explore licensing agreements with Pfizer to utilize the patented technology for developing combination products, assuming such agreements are feasible.
- Patent Expiration: The expiration of US Patent 7,799,761 on October 21, 2025, will open opportunities for generic or biosimilar (if applicable) versions of such combination therapies. Companies could begin planning for generic entry strategies in anticipation of this date.
Investment Implications:
- Market Entry Barriers: The existence of this patent presents a barrier to entry for new products specifically targeting the claimed SERM-bisphosphonate combinations. Investors should assess the strength and remaining lifespan of this patent when evaluating companies in the bone health space.
- Pfizer's Market Position: The patent bolsters Pfizer's potential market position in the SERM-bisphosphonate combination therapy space. Investors holding or considering Pfizer stock should be aware of the intellectual property supporting their portfolio in this therapeutic area.
- Risk Assessment: For companies with existing or pipeline products that might infringe this patent, there is a litigation risk. Investors should factor in potential legal expenses and the possibility of injunctions or damages.
- Emerging Opportunities: As the patent approaches expiration, investments in companies preparing to launch generic versions of such combination therapies could become attractive, assuming a robust market demand and successful generic development.
- Diversification: Investors may consider diversifying their portfolios to include companies focusing on alternative mechanisms of action for bone health, thereby mitigating risks associated with patents like 7,799,761.
The patent's claims, particularly the combination of raloxifene and alendronate, and its method of use claims, indicate a targeted strategy to protect a specific therapeutic approach. Understanding the precise wording of these claims and the patent's expiration date is crucial for strategic decision-making.
Key Takeaways
- US Patent 7,799,761 protects pharmaceutical compositions and methods of use involving combinations of Selective Estrogen Receptor Modulators (SERMs) and bisphosphonates.
- Key claims cover compositions containing specific SERMs (e.g., raloxifene) and bisphosphonates (e.g., alendronate) and methods for treating osteoporosis and increasing bone mineral density.
- The patent's stated therapeutic rationale is the synergistic effect of combining these two drug classes for enhanced bone health benefits.
- The patent expires on October 21, 2025, limiting its period of market exclusivity.
- The competitive landscape includes major pharmaceutical companies with patents on individual SERMs and bisphosphonates, but US Patent 7,799,761 specifically targets the combination.
- R&D and investment decisions require careful freedom-to-operate analysis, consideration of differentiation strategies, and anticipation of patent expiration for future market entry.
Frequently Asked Questions
-
What is the primary therapeutic use protected by US Patent 7,799,761?
The primary therapeutic uses protected are the treatment and prevention of bone disease, specifically osteoporosis, and the method for increasing bone mineral density.
-
Does US Patent 7,799,761 cover administering raloxifene and alendronate separately?
The patent claims specific pharmaceutical compositions, but also methods of treatment. If separate administration of raloxifene and alendronate is conducted in a manner that infringes the claimed method of treatment, then it could be covered. However, the strongest protection is likely for a fixed-dose combination product.
-
When does US Patent 7,799,761 expire, and what happens after that date?
US Patent 7,799,761 expires on October 21, 2025. After this date, the patent protection lapses, potentially allowing for the development and marketing of generic versions of the claimed combination therapies without infringing this specific patent.
-
Are there any currently marketed fixed-dose combination drugs that directly fall under the claims of US Patent 7,799,761?
As of the current analysis, widely marketed standalone fixed-dose combination prescription drugs comprising a SERM and a bisphosphonate are not prevalent. This patent may have been filed to support future product development or to defend specific combination strategies.
-
What are the risks for a company developing a new osteoporosis drug that combines a SERM and a bisphosphonate before October 2025?
The primary risk is patent infringement. A company developing such a drug would need to ensure its product composition and/or method of use does not fall within the scope of claims 1-9 of US Patent 7,799,761, or conduct a thorough freedom-to-operate analysis and potentially seek a license or design around the patent.
Citations
[1] Pfizer Inc. (2009). Pharmaceutical compositions containing a selective estrogen receptor modulator and a bisphosphonate (U.S. Patent No. 7,799,761). Washington, DC: U.S. Patent and Trademark Office.
More… ↓
⤷ Start Trial
|
